Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

Tanya Paquet, Claire Le Manach, Diego González Cabrera, Yassir Younis, Philipp P. Henrich, Tara S Abraham, Marcus C S Lee, Rajshekhar Basak, Sonja Ghidelli-Disse, María José Lafuente-Monasterio, Marcus Bantscheff, Andrea Ruecker, Andrew M Blagborough, Sara E Zakutansky, Anne-Marie Zeeman, Karen L White, David M Shackleford, Janne Mannila, Julia Morizzi, Christian Scheurer & 1 others Susan A Charman

Research output: Contribution to journalArticleResearchpeer-review

Abstract

As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-Aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-To-mouse transmission were achieved in the Plasmodium berghei mouse model. Experiments in monkeys revealed the ability of MMV390048 to be used for full chemoprotection. Although MMV390048 was not able to eliminate liver hypnozoites, it delayed relapse in a Plasmodium cynomolgi monkey model.Both genomic andchemoproteomic studies identified a kinase of the Plasmodium parasite, phosphatidylinositol 4-kinase, as the molecular target of MMV390048. The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.

Original languageEnglish
Article numbereaad9735
Number of pages14
JournalScience Translational Medicine
Volume9
Issue number387
DOIs
Publication statusPublished - 26 Apr 2017

Cite this

Paquet, Tanya ; Le Manach, Claire ; Cabrera, Diego González ; Younis, Yassir ; Henrich, Philipp P. ; Abraham, Tara S ; Lee, Marcus C S ; Basak, Rajshekhar ; Ghidelli-Disse, Sonja ; Lafuente-Monasterio, María José ; Bantscheff, Marcus ; Ruecker, Andrea ; Blagborough, Andrew M ; Zakutansky, Sara E ; Zeeman, Anne-Marie ; White, Karen L ; Shackleford, David M ; Mannila, Janne ; Morizzi, Julia ; Scheurer, Christian ; Charman, Susan A. / Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. In: Science Translational Medicine. 2017 ; Vol. 9, No. 387.
@article{100a2397e8ab4553928e48aeb89eb76c,
title = "Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase",
abstract = "As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-Aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-To-mouse transmission were achieved in the Plasmodium berghei mouse model. Experiments in monkeys revealed the ability of MMV390048 to be used for full chemoprotection. Although MMV390048 was not able to eliminate liver hypnozoites, it delayed relapse in a Plasmodium cynomolgi monkey model.Both genomic andchemoproteomic studies identified a kinase of the Plasmodium parasite, phosphatidylinositol 4-kinase, as the molecular target of MMV390048. The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.",
author = "Tanya Paquet and {Le Manach}, Claire and Cabrera, {Diego Gonz{\'a}lez} and Yassir Younis and Henrich, {Philipp P.} and Abraham, {Tara S} and Lee, {Marcus C S} and Rajshekhar Basak and Sonja Ghidelli-Disse and Lafuente-Monasterio, {Mar{\'i}a Jos{\'e}} and Marcus Bantscheff and Andrea Ruecker and Blagborough, {Andrew M} and Zakutansky, {Sara E} and Anne-Marie Zeeman and White, {Karen L} and Shackleford, {David M} and Janne Mannila and Julia Morizzi and Christian Scheurer and Charman, {Susan A}",
year = "2017",
month = "4",
day = "26",
doi = "10.1126/scitranslmed.aad9735",
language = "English",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "387",

}

Paquet, T, Le Manach, C, Cabrera, DG, Younis, Y, Henrich, PP, Abraham, TS, Lee, MCS, Basak, R, Ghidelli-Disse, S, Lafuente-Monasterio, MJ, Bantscheff, M, Ruecker, A, Blagborough, AM, Zakutansky, SE, Zeeman, A-M, White, KL, Shackleford, DM, Mannila, J, Morizzi, J, Scheurer, C & Charman, SA 2017, 'Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase' Science Translational Medicine, vol. 9, no. 387, eaad9735. https://doi.org/10.1126/scitranslmed.aad9735

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. / Paquet, Tanya; Le Manach, Claire; Cabrera, Diego González; Younis, Yassir; Henrich, Philipp P.; Abraham, Tara S; Lee, Marcus C S; Basak, Rajshekhar; Ghidelli-Disse, Sonja; Lafuente-Monasterio, María José; Bantscheff, Marcus; Ruecker, Andrea; Blagborough, Andrew M; Zakutansky, Sara E; Zeeman, Anne-Marie; White, Karen L; Shackleford, David M; Mannila, Janne; Morizzi, Julia; Scheurer, Christian; Charman, Susan A.

In: Science Translational Medicine, Vol. 9, No. 387, eaad9735, 26.04.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

AU - Paquet, Tanya

AU - Le Manach, Claire

AU - Cabrera, Diego González

AU - Younis, Yassir

AU - Henrich, Philipp P.

AU - Abraham, Tara S

AU - Lee, Marcus C S

AU - Basak, Rajshekhar

AU - Ghidelli-Disse, Sonja

AU - Lafuente-Monasterio, María José

AU - Bantscheff, Marcus

AU - Ruecker, Andrea

AU - Blagborough, Andrew M

AU - Zakutansky, Sara E

AU - Zeeman, Anne-Marie

AU - White, Karen L

AU - Shackleford, David M

AU - Mannila, Janne

AU - Morizzi, Julia

AU - Scheurer, Christian

AU - Charman, Susan A

PY - 2017/4/26

Y1 - 2017/4/26

N2 - As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-Aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-To-mouse transmission were achieved in the Plasmodium berghei mouse model. Experiments in monkeys revealed the ability of MMV390048 to be used for full chemoprotection. Although MMV390048 was not able to eliminate liver hypnozoites, it delayed relapse in a Plasmodium cynomolgi monkey model.Both genomic andchemoproteomic studies identified a kinase of the Plasmodium parasite, phosphatidylinositol 4-kinase, as the molecular target of MMV390048. The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.

AB - As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-Aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-To-mouse transmission were achieved in the Plasmodium berghei mouse model. Experiments in monkeys revealed the ability of MMV390048 to be used for full chemoprotection. Although MMV390048 was not able to eliminate liver hypnozoites, it delayed relapse in a Plasmodium cynomolgi monkey model.Both genomic andchemoproteomic studies identified a kinase of the Plasmodium parasite, phosphatidylinositol 4-kinase, as the molecular target of MMV390048. The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.

UR - http://www.scopus.com/inward/record.url?scp=85018309975&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aad9735

DO - 10.1126/scitranslmed.aad9735

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 387

M1 - eaad9735

ER -